Marisa Stachelski dismissed her bloating as irritable bowel syndrome for months. At 37, the symptom that seemed routine turned into a colon cancer diagnosis. The shock deepened when genetic testing revealed she carried a BRCA2 mutation, a gene variant that dramatically raises cancer risk across multiple organs.
Her story illuminates how rare cancers strike younger people and how genetic factors shape disease risk in ways many patients never anticipate.
Stachelski experienced persistent bloating and digestive issues that fit the IBS profile. She sought medical attention, but initial evaluations didn't reveal the underlying problem. When doctors finally performed a colonoscopy, they discovered a tumor. The cancer was caught at stage 1, which improved her treatment outlook substantially. But the diagnosis prompted comprehensive genetic testing that uncovered the BRCA2 mutation she carried.
BRCA2 mutations are hereditary genetic changes that increase the likelihood of breast and ovarian cancer in women, but they also elevate colon cancer risk. People with BRCA2 mutations face roughly three to six times higher colorectal cancer risk compared to the general population, according to research published in medical genetics literature. The mutation accounts for only 3 to 5 percent of all colorectal cancers, but its impact on individual carriers is profound.
The discovery raised urgent questions about her medical management moving forward. Stachelski now faces more intensive screening protocols and potentially different preventive strategies. Her case highlights a critical gap in cancer prevention: many people develop tumors without knowing they carry high-risk genetic mutations. Genetic counselors and oncologists increasingly recommend testing for anyone diagnosed with colorectal cancer before age 50, especially those without strong family histories, since hereditary factors may not be obvious.
BRCA2 carriers benefit from earlier and more frequent colonoscopies. Standard colorectal screening begins at age 45 for average-risk individuals, but carriers require closer monitoring starting much younger. Some experts recommend baseline colonoscopies in the 30s for known carriers. Stachelski's case demonstrates why this proactive approach matters: earlier detection improves survival rates and reduces treatment intensity.
The psychological weight of a genetic diagnosis extends beyond physical health. Stachelski must now consider implications for her blood relatives. BRCA2 mutations follow an autosomal dominant inheritance pattern, meaning each parent, sibling, or child of a carrier has a 50 percent chance of inheriting the same mutation. Her diagnosis opens conversations her family may need to have about genetic testing and heightened surveillance.
Her experience also speaks to how persistent digestive symptoms warrant investigation even when they seem benign. Bloating occupies a gray zone in medicine. Doctors hear it constantly, and most cases reflect functional disorders rather than serious disease. But dismissing symptoms without investigation risks missing early-stage cancers when treatment succeeds most often.
Stachelski's journey from unexplained bloating to BRCA2 diagnosis underscores that cancer risk involves both individual factors and hereditary patterns. Young people with digestive complaints deserve thorough evaluation. Those diagnosed with early-stage colorectal cancer should access genetic testing. And families with inherited cancer syndromes benefit from proactive screening protocols that catch disease when treatment options expand and prognosis improves.